Analyst Research on Teva Pharmaceutical Industries Limited and Forest Laboratories Inc. - Mixed Results for Drug Manufacturers
May 16 2012 - 8:25AM
Marketwired
www.stockcall.com/ offers investors comprehensive research on the
Drug Manufacturers - Other industry and has completed analytical
research on
Teva Pharmaceutical Industries
Limited (NASDAQ: TEVA) and
Forest
Laboratories Inc. (NYSE: FRX). Register with us today at
www.stockcall.com/ to have free access to these researches.
Weakness in the European markets continues to weigh on drug
manufacturers but several companies still turned in impressive
first quarter results. Register now at
https://stockcall.com/development/stockcall/page.php?name=register.html
to have free access to our reports on the Drug Manufacturers -
Other industry.
www.stockcall.com/ is an online platform where investors doing
their due-diligence on the Drug Manufacturers - Other industry can
have easy and free access to our analyst research and opinions on
Teva Pharmaceutical Industries Limited and Forest Laboratories
Inc.; all investors need to do is register for a complimentary
membership at
https://stockcall.com/development/stockcall/page.php?name=register.html.
Teva Pharmaceutical Industries Ltd. saw impressive sales growth
in its first quarter of the year and efforts to streamline its
operations might lead to significant gains in the second half of
the year. European sales lagged and fell 2% but the company has
done an excellent job improving operating efficiency while growing
sales and maintaining a steady pipeline of drugs to market.
Investors looking for free research on Teva
Pharmaceutical Industries Limited are welcome to sign up at
www.stockcall.com/TEVA160512.pdf for our new report.
The importance of getting new drugs to market was exemplified in
rival Forest Laboratories Inc. weak quarterly performance. The
company saw revenues fall 7.3% as it struggled with expiring patent
protection. Investors looking for complimentary research on
Forest Laboratories Inc. are welcome to sign
up at www.stockcall.com/FRX160512.pdf for our new report.
Moving forward, economic improvements in Europe would certainly
be welcomed by the industry but growth in the coming months still
looks feasible with or without a turnaround from the region.
Competition and maintaining a steady pipeline of drugs to market
will likely continue to be key factors for drug makers in the near
term. Visit www.stockcall.com/ to see how companies in this
industry have grown over the past years and how they are expected
to perform in the future.
About StockCall.com
StockCall.com is a financial website where investors can have
easy, precise and comprehensive research and opinions on stocks
making the headlines.
Contact Person: William T. Knight
stockcall2010@gmail.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2023 to Sep 2024